Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Total Assets
Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) holds total assets worth CN¥8.25 Billion CNY (≈ $1.21 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 600867 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Tonghua Dongbao Pharmaceutical Co Ltd - Total Assets Trend (1994–2025)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Tonghua Dongbao Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Tonghua Dongbao Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Tonghua Dongbao Pharmaceutical Co Ltd's total assets of CN¥8.25 Billion consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.1% |
| Accounts Receivable | CN¥409.02 Million | 5.2% |
| Inventory | CN¥704.22 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.64 Billion | 20.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Tonghua Dongbao Pharmaceutical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tonghua Dongbao Pharmaceutical Co Ltd's current assets represent 34.7% of total assets in 2025, a decrease from 77.1% in 1994.
- Cash Position: Cash and equivalents constituted 18.1% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 20.8% of total assets.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Tonghua Dongbao Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
Tonghua Dongbao Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.84 | 2.89 | 7.50 |
| Quick Ratio | 3.85 | 1.85 | 5.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.43 Billion | CN¥1.37 Billion | CN¥1.78 Billion |
Tonghua Dongbao Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tonghua Dongbao Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.03 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 7.2% |
| Total Assets | CN¥7.91 Billion |
| Market Capitalization | $2.14 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tonghua Dongbao Pharmaceutical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tonghua Dongbao Pharmaceutical Co Ltd's assets grew by 7.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tonghua Dongbao Pharmaceutical Co Ltd (1994–2025)
The table below shows the annual total assets of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.91 Billion ≈ $1.16 Billion |
+7.15% |
| 2024-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
-5.06% |
| 2023-12-31 | CN¥7.77 Billion ≈ $1.14 Billion |
+15.13% |
| 2022-12-31 | CN¥6.75 Billion ≈ $987.78 Million |
+3.53% |
| 2021-12-31 | CN¥6.52 Billion ≈ $954.10 Million |
+12.35% |
| 2020-12-31 | CN¥5.80 Billion ≈ $849.20 Million |
+8.47% |
| 2019-12-31 | CN¥5.35 Billion ≈ $782.86 Million |
-2.08% |
| 2018-12-31 | CN¥5.46 Billion ≈ $799.46 Million |
+14.95% |
| 2017-12-31 | CN¥4.75 Billion ≈ $695.47 Million |
+1.66% |
| 2016-12-31 | CN¥4.68 Billion ≈ $684.10 Million |
+23.41% |
| 2015-12-31 | CN¥3.79 Billion ≈ $554.32 Million |
+28.14% |
| 2014-12-31 | CN¥2.96 Billion ≈ $432.59 Million |
+9.72% |
| 2013-12-31 | CN¥2.69 Billion ≈ $394.28 Million |
+13.21% |
| 2012-12-31 | CN¥2.38 Billion ≈ $348.29 Million |
+0.12% |
| 2011-12-31 | CN¥2.38 Billion ≈ $347.88 Million |
+8.74% |
| 2010-12-31 | CN¥2.19 Billion ≈ $319.93 Million |
-2.89% |
| 2009-12-31 | CN¥2.25 Billion ≈ $329.46 Million |
+3.69% |
| 2008-12-31 | CN¥2.17 Billion ≈ $317.73 Million |
-4.31% |
| 2007-12-31 | CN¥2.27 Billion ≈ $332.02 Million |
+15.35% |
| 2006-12-31 | CN¥1.97 Billion ≈ $287.85 Million |
+4.36% |
| 2005-12-31 | CN¥1.88 Billion ≈ $275.83 Million |
+4.36% |
| 2004-12-31 | CN¥1.81 Billion ≈ $264.31 Million |
+0.62% |
| 2003-12-31 | CN¥1.80 Billion ≈ $262.68 Million |
+14.45% |
| 2002-12-31 | CN¥1.57 Billion ≈ $229.53 Million |
+7.69% |
| 2001-12-31 | CN¥1.46 Billion ≈ $213.13 Million |
-0.86% |
| 2000-12-31 | CN¥1.47 Billion ≈ $214.98 Million |
-1.89% |
| 1999-12-31 | CN¥1.50 Billion ≈ $219.12 Million |
+27.04% |
| 1998-12-31 | CN¥1.18 Billion ≈ $172.48 Million |
+34.71% |
| 1997-12-31 | CN¥875.03 Million ≈ $128.04 Million |
+76.45% |
| 1996-12-31 | CN¥495.92 Million ≈ $72.57 Million |
+51.44% |
| 1995-12-31 | CN¥327.48 Million ≈ $47.92 Million |
+22.87% |
| 1994-12-31 | CN¥266.52 Million ≈ $39.00 Million |
-- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more